tiprankstipranks
Trending News
More News >
Eli Lilly & Co (LLY)
NYSE:LLY
US Market

Eli Lilly & Co (LLY) Earnings Dates, Call Summary & Reports

Compare
15,958 Followers

Earnings Data

Report Date
Aug 07, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
5.54
Last Year’s EPS
3.92
Same Quarter Last Year
Based on 19 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:May 01, 2025
|
% Change Since: -13.77%
|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call presented strong financial growth driven by key products, successful trial results, and significant investments in manufacturing. However, challenges remain with regulatory hurdles, potential tariff impacts, and market dynamics in the obesity segment. The balance of positive revenue growth and strategic investments against these challenges suggests a cautiously optimistic outlook.
Company Guidance
During the Q1 2025 earnings call, Eli Lilly & Company reported a robust financial performance with a 45% increase in revenue compared to Q1 2024, driven by key products like Mounjaro, Zepbound, and Verzenio. The company's gross margin was 83.5%, with marketing expenses increasing by 26% and R&D expenses by 8%. Lilly achieved several pipeline milestones, including the approval of Omvoh in the U.S., EU, and Japan. They also announced significant U.S. manufacturing investments exceeding $50 billion since 2020. Despite the impact of acquired IPR&D charges reducing earnings per share by $1.72, the company delivered an EPS of $3.34. Looking ahead, Lilly anticipates further clinical trial readouts for orforglipron and potential regulatory submissions for obesity treatments by year-end 2025, while maintaining a focus on expanding their product pipeline and manufacturing capabilities.
Strong Revenue Growth
Revenue grew 45% compared to Q1 of 2024, driven by key products like Mounjaro and Zepbound, which contributed over $4 billion in growth and accounted for $7.5 billion of the company's revenue.
Phase 3 Orforglipron Trial Success
Orforglipron achieved significant results in its Phase 3 trial for Type 2 diabetes, with hemoglobin A1c reductions of 1.3% to 1.6% and weight loss of approximately 16 pounds or 7.9% body weight at the highest dose.
Manufacturing Investment Expansion
Lilly announced over $50 billion in new U.S. manufacturing investments since 2020, including plans to build four new facilities, three of which will be active pharmaceutical ingredient facilities.
Strong Performance of Mounjaro and Zepbound
Mounjaro sales were $3.8 billion, more than double the same quarter last year, and Zepbound sales increased by $1.8 billion to $2.3 billion, making it the U.S. market leader in anti-obesity prescriptions.
Strong Financial Performance Metrics
Gross margin increased to 83.5% in Q1, and the non-GAAP performance margin was 42.6%, an increase of over 11 percentage points from Q1 2024.
---

Eli Lilly & Co (LLY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

LLY Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 07, 20252025 (Q2)
5.54 / -
3.92
May 01, 20252025 (Q1)
3.26 / 3.34
2.5829.46% (+0.76)
Feb 06, 20252024 (Q4)
5.04 / 5.32
2.49113.65% (+2.83)
Oct 30, 20242024 (Q3)
1.42 / 1.18
0.11080.00% (+1.08)
Aug 08, 20242024 (Q2)
2.74 / 3.92
2.1185.78% (+1.81)
Apr 30, 20242024 (Q1)
2.47 / 2.58
1.6259.26% (+0.96)
Feb 06, 20242023 (Q4)
2.30 / 2.49
2.0919.14% (+0.40)
Nov 02, 20232023 (Q3)
-0.18 / 0.10
1.98-94.95% (-1.88)
Aug 08, 20232023 (Q2)
1.98 / 2.11
1.2568.80% (+0.86)
Apr 27, 20232023 (Q1)
1.73 / 1.62
2.62-38.17% (-1.00)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

LLY Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 01, 2025$898.95$794.10-11.66%
Feb 06, 2025$840.73$868.87+3.35%
Oct 30, 2024$900.53$843.98-6.28%
Aug 08, 2024$768.46$841.28+9.48%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Eli Lilly & Co (LLY) report earnings?
Eli Lilly & Co (LLY) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
    What is Eli Lilly & Co (LLY) earnings time?
    Eli Lilly & Co (LLY) earnings time is at Aug 07, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is LLY EPS forecast?
          LLY EPS forecast for the fiscal quarter 2025 (Q2) is 5.54.
            ---

            Eli Lilly & Co (LLY) Earnings News

            NVO Earnings: Novo Nordisk Stock Rises Despite Cutting Fiscal 2025 Outlook
            Premium
            Market News
            NVO Earnings: Novo Nordisk Stock Rises Despite Cutting Fiscal 2025 Outlook
            18h ago
            LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments
            Premium
            Market News
            LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments
            3M ago
            LLY Earnings: Eli Lilly Plunges on Disappointing Q3 Results, Lowers Outlook
            Premium
            Market News
            LLY Earnings: Eli Lilly Plunges on Disappointing Q3 Results, Lowers Outlook
            6M ago
            LLY Earnings: Eli Lilly Gains on Strong Q1 Earnings Beat
            Premium
            Market News
            LLY Earnings: Eli Lilly Gains on Strong Q1 Earnings Beat
            1y ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis